Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited announced a Board meeting on July 22, 2026, to consider its Un-audited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. In accordance with SEBI regulations, the trading window for dealing in the company's securities will be closed from June 24, 2026, to July 24, 2026. This routine intimation ensures compliance and prevents insider trading prior to the financial results disclosure.

Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited has announced the publication of newspaper advertisements concerning its upcoming 42nd Annual General Meeting (AGM). These advertisements provide the official notice for the AGM, which will be conducted through video conference. Crucially for shareholders, the notice also includes information regarding the record date and the final dividend proposed by the company. This announcement is significant for investors, providing key details for determining dividend eligibility and participating in the annual meeting.

Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited announced the allotment of 6,730 fully paid-up equity shares, each with a face value of Re.1/-. These shares were issued on June 19, 2026, to eligible employees who exercised their stock options under the company's ESOP Schemes from 2002 and 2007. This routine event reflects the company's commitment to employee incentive and retention programs. For investors, this results in a minor increase in the total outstanding shares, leading to a negligible dilution of existing equity.